SCHEMBL31522992

SCHEMBL31522992

CCOC(=O)c1nn(-c2ccc(C(C)C)cc2)c2c1CN(C(=O)OC(C)(C)C)CC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MEN1 O00255 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
NPBWR1 P48145 1/20 0.44
MAP3K14 Q99558 1/20 0.43
ADORA1 P30542 1/20 0.43
GPR119 Q8TDV5 2/20 0.42
TP53 P04637 2/20 0.41
POLB P06746 1/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
MAPT P10636 1/20 0.40
MAPK1 P28482 1/20 0.40
HTT P42858 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
CYP1A2 P05177 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31522871 0.89 ALDH1A1 (0.45) ALDH1A1NPSR1MEN1LMNAGAA
SCHEMBL12602495 0.89 ALDH1A1 (0.47) ALDH1A1NPSR1MEN1LMNAGAA
SCHEMBL31523026 0.88 ADORA1 (0.41) ALDH1A1LMNASMN1; SMN2MAP3K14ADORA1
SCHEMBL31523291 0.87 ALDH1A1 (0.41) ALDH1A1NPSR1MEN1LMNAGAA
SCHEMBL4794737 0.87 ADORA1 (0.48) ALDH1A1NPSR1MEN1LMNAGAA
SCHEMBL4795149 0.86 SLC5A1 (0.44) ALDH1A1NPSR1MEN1LMNAGAA
SCHEMBL31523305 0.86 ALDH1A1 (0.40) ALDH1A1NPSR1MEN1LMNAGAA
SCHEMBL31523467 0.86 ALDH1A1 (0.40) ALDH1A1NPSR1MEN1LMNAGAA
SCHEMBL31523222 0.85 MEN1 (0.47) ALDH1A1NPSR1MEN1LMNAGAA
SCHEMBL31523611 0.84 ESR2 (0.45) ALDH1A1NPSR1MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2025-11-13 US disclosed
WO-2025054488-A1 TRICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2025-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346600-A1 TRICYCLIC DERIVATIVES AND RELATED USES WRN, RECQL, BLM ALDH1A1 1509/4885NPSR1 4544/4885MEN1 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.